GlobeNewswire Inc.··Telix Pharmaceuticals LimitedTelix Resubmits FDA Application for Brain Cancer Imaging Drug Pixclara
Telix resubmits FDA application for Pixclara, a brain cancer imaging agent with Orphan Drug and Fast Track designations, addressing a regulatory Complete Response Letter.
TLXorphan drug designationradiopharmaceuticals